Genetic Polymorphisms in Human Drug-Metabolizing Enzymes: Potential Uses of Reverse Genetics to Identify Genes of Toxicological Relevance

References

• Kalow W. Pharmacogenetics: its biological roots and the medical challenge. Clin. Pharmacol. Ther. 1993; 54: 235
   PubMedGoogle Scholar
• Kalow W. Life of a pharmacologist or the rich life of a poor metabolizer (invited autobiographical account). Pharmacol. Toxicol 1995; 76: 221
   Google Scholar
• Motulsky A. G. Pharmacogenetics and ecogenetics in 1991. Pharmacogenetics 1991; 1: 2
   Google Scholar
• Caporaso N. E., Goldstein A. Cancer genes: single and susceptibility: exposing the difference. Pharmacogenetics 1995; 5: 59
   PubMedGoogle Scholar
• Nebert D. W., Gonzalez F. J. P450 genes. Structure, evolution and regulation. Annu. Rev. Biochem. 1987; 56: 945
   PubMed Web of Science ®Google Scholar
• Nebert D. W., McKinnon R. A. Cytochrome P450: evolution and functional diversity. Prog. Liver Dis. 1994; 12: 63
   PubMedGoogle Scholar
• Nelson D. R., Kamataki T., Waxman D. J., Guengerlch F. P., Estabrook R. W., Feyereisen R., Gonzalez F. J., Coon M. J., Gunsalus I. C., Gotoh O., et al. The P450 superfamily: update on new sequences, gane mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993; 12: 1
   PubMed Web of Science ®Google Scholar
• Nebert D. W., Nelson D. R., Coon M. J., Estabrook R. W., Feyereisen R., Fujii-Kuriyama Y., Gonzalez F. J., Guengerich F. P., Gunsalus I. C., Johnson E. F., et al. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol 1991; 10: 1
   PubMed Web of Science ®Google Scholar
• Lawton M. P., Cashman J. R., Cresteil T., Dolphin C. T., Elfarra A. A., Hines R. N., Hodgson E., Kimura T., Ozols J., Phillips I. R., et al. Mammalian flavin-containing monooxygenase gene families based on amino acid sequence identities. Arch. Biochem. Biophys. 1994; 308: 254
   PubMed Web of Science ®Google Scholar
• Burchell B., Nebert D. W., Nelson D. R., Bock K. W., Iyanagi T., Jansen P. L. M., Lancet D., Mulder G. J., Chowdhury J. R., Siest G., et al. The UDP-glucuronosyltransferase gene superfamily: suggested nomenclature based on evolutionary divergence. DNA Cell Biol 1991; 10: 487
   PubMed Web of Science ®Google Scholar
• Nebert D. W. Identification of genetic differences in drug metabolism: prediction of individual risk of toxicity or cancer. Hepatology 1991; 14: 398
   Google Scholar
• Nebert D. W. Role of genetics and drug metabolism in human cancer risk. Mutat. Res. 1991; 247: 267
   PubMed Web of Science ®Google Scholar
• Nebert D. W. The Ahlocus: genetic differences in toxicity, cancer, mutation, and birth defects. Crit. Rev. Toxicol. 1989; 20: 153
   PubMed Web of Science ®Google Scholar
• Nebert D. W., Petersen D. D., Puga A. Human AH locus polymorphism and cancer: inducibility ofCYP1A1 and other genes by combustion products and dioxin. Pharmacogenetics 1991; 1: 68
   PubMedGoogle Scholar
• Gonzalez F. J. The molecular biology of cytochrome P450s. Pharmacol. Rev. 1988; 40: 243
   PubMed Web of Science ®Google Scholar
• Greenlee W. F., Neal R. A. The Ahreceptor: a biochemical and biological perspective. The Receptors, P. M. Conn. Academic-Press, New York 1985; Vol. 2: 89
   Google Scholar
• Burbach K. ML, Poland A., Bradfield C. A. Cloning of the Ah-receptor cDNA reveals a distinctive ligand-activated transcription factor. Proc. Natl. Acad. Sci. U.S.A. 1992; 89: 8185
   PubMed Web of Science ®Google Scholar
• Ema M., Sogawa K., Watanabe N., Chujoh Y., Matsushita N., Gotoh O., Funae Y., Fujii-Kuriyama Y. cDNA cloning and structure of mouse putative Ah receptor. Biochem. Biophys. Res. Commitn. 1992; 184: 246
   PubMed Web of Science ®Google Scholar
• Hankinson O. Research on the aryl hydrocarbon (dioxin) receptor is primed to take off. Arch. Biochem. Biophys. 1993; 300: 1
   PubMed Web of Science ®Google Scholar
• Swanson H. I., Bradfield C. A. The AH-recep-tor: genetics, structure and function. Pharmacogenetics 1993; 3: 213
   PubMedGoogle Scholar
• Landers J. P., Bunce N. J. The Ahreceptor and the mechanism of dioxin toxicity. Biochem. J. 1991; 276: 273
   PubMed Web of Science ®Google Scholar
• Nebert D. W., Puga A., Vasiliou V. Role of the Ah receptor and dioxin inducible[Ah] gene battery in toxicity, cancer, and signal transduction.Ann. /V. Y. Acad. Sci. 1993; 685: 624
   PubMed Web of Science ®Google Scholar
• Whitlock J. P., Jr. Genetic and molecular aspects of 2.3.7,K-tetrachlorodibenzo-p-dioxin action. Anna. Rev. Pharmacol. Toxicol 1991; 30: 251
   Google Scholar
• Poland A., Glover E., Robinson J. R., Nebert D. W. Genetic expression of aryl hydrocarbon hydroxylase activity. Induction of monooxygenase activities and cytochrome P,-450 formation by 2.3.7.8-tetrachlorodibenzo-/j-dioxin in mice genetically “non-responsive” to other aromatic hydrocarbons. J. Biol. Chem. 1974; 249: 5599
   PubMed Web of Science ®Google Scholar
• Poland A., Palen D., Glover E. Analysis of the four alleles of the murine aryl hydrocarbon receptor. Mol. Pharmacol. 1994; 46: 915
   PubMed Web of Science ®Google Scholar
• Ema M., Ohe N., Suzuki M., Mimura J., Sogawa K., Ikawa S., Fujii-Kuriyama Y. Dioxin binding activities of polymorphic forms of mouse and human arylhydrocarbon receptors. J. Biol. Chem. 1994; 269: 27337
   PubMed Web of Science ®Google Scholar
• Chang C. Y., Smith D. R., Prasad V. S., Sidman C. L., Nebert D. W., Puga A. Ten nucleotide differences, five of which cause amino acid changes. are associated with the Ah receptor locus polymorphism of C57BL/6 and DBA/2 mice. Pharmacogenetics 1993; 3: 312
   PubMedGoogle Scholar
• Roberts E. A., Golas C. L., Okey A. B. Ahreceptor mediated induction of aryl hydrocarbon hydroxylase: detection in human lung by binding of 2,3,7.8-[-,H]tetrachlorodibenzo-p-dioxin. Cancer Res. 1986; 46: 3739
   PubMed Web of Science ®Google Scholar
• Vanden Heuvel J. P., Clark G. C., Thompson C. L., McCoy Z., Miller C. R., Lucier G. W., Bell D. A. CYP1 Al mRNA levels as a human exposure biomarker: use of quantitative polymerase chain reaction to measure CYP1A1 expression in human peripheral blood lymphocytes. Carcinogenesis 1993; 14: 2003
   PubMed Web of Science ®Google Scholar
• Kellerman G., Shaw C. R., Luyten-Kellerman M. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N. Engl. J. Med. 1973; 289: 934
   PubMed Web of Science ®Google Scholar
• Fingerhut M. A., Halperin W. E., Marlow D. A., Piacitelli L. A., Honchar P. A., Sweeney M. H., Greife A. L., Dill P. A., Steenland K., Suruda A. J. Cancer mortality in workers exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. N. Engl. J. Med. 1991; 324: 212
   PubMed Web of Science ®Google Scholar
• Manz A., Berger J., Dwyer J. H., Flesch-Janys D., Nagel S., Waltsgott H. Cancer mortality among workers in chemical plant contaminated with dioxin. Lancet 1991; 338: 959
   PubMed Web of Science ®Google Scholar
• Bertazzi P. A. Long-term effects of chemical disasters. Lessons and results from Seveso. Sci. Total Environ. 1991; 106: 5
   PubMed Web of Science ®Google Scholar
• Kouri R. E., McKinney C. E., Slomiany D. J., Snodgrass D. R., Wray N. P., McLemore T. L. Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes. Cancer Res. 1982; 42: 5030
   PubMed Web of Science ®Google Scholar
• Coombs M. L., Mason W. A., Muijsson I. E., Cantrell E. T., Anderson D. E., Busbee D. L. Aryl hydrocarbon hydroxylase and testosterone 16oc-hydroxylase in cultured human lymphocytes. Biochem. Genet. 1976; 14: 671
   Google Scholar
• Guirgis H. A., Lynch H. T., Mate T., Harris R. E., Wells I., Caha L., Anderson J., Maloney K., Rankin L. Aryl hydrocarbon hydroxylase activity in lymphocytes from lung cancer patients and normal controls. Oncology 1976; 33: 105
   PubMed Web of Science ®Google Scholar
• Emery A. E. H., Danford N., Anand R., Duncam W., Paton L. Aryl hydrocarbon hydroxylase inducibility in patients with cancer. Lancet 1978; 1: 470
   PubMed Web of Science ®Google Scholar
• Korsgaard R., Trell E. Aryl hydrocarbon hydroxylase and bronchogenic carcinomas associated with smoking. Lancet 1978; 1: 1103
   Google Scholar
• Arnott M. S., Yamauchi T., Johnston D. A. Aryl hydrocarbon hydroxylase in normal and cancer populations. Carcinogens: Identification and Mechanisms of Action, A. C. Griffin, C. R Shaw. Raven Press, New York 1979; 145
   Google Scholar
• Gahmberg C. G., Sekki A., Kosunen T. U., Holsti L. R., Makela O. Induction of aryl hydrocarbon hydroxylase activity and pulmonary carcinoma. Int. J. Cancer 1979; 23: 302
   PubMed Web of Science ®Google Scholar
• McLemore T. L., Martin R. R., Springer R. R., Wray N., Cantrell E. T., Busbee D. L. Aryl hydrocarbon hydroxylase acticity in pulmonary alveolar macrophages and lymphocytes from lung cancer and noncancer patients. Biochem. Genet. 1979; 17: 795
   PubMed Web of Science ®Google Scholar
• Trell E., Körsgaard R., Hood B., Kitzing P., Norden G., Simonsson B. G. Aryl hydrocarbon hydroxylase inducibility and laryngeal carcinomas. Lancet 1976; 2: 140
   Google Scholar
• Trell E., Körsgaard R. Smoking and oral carcinoma. Lancet 1978; 1: 671
   Google Scholar
• Trell E., Körsgaard R., Kitzing P., Lundgren K., Mattiasson I. Aryl hydrocarbon inducibility and carcinoma of oral cavity. Lancet 1978; 1: 109
   PubMedGoogle Scholar
• Shields P. G., Sugimura H., Caporaso N. E., Petruzzelli S. F., Bowman E. D., Trump B. F., Weston A., Harris C. Polycyclic aromatic hydrocarbon-DNA adducts and theCYP1AI RFLP. Environ. Health Perspect 1992; 98: 191
   PubMed Web of Science ®Google Scholar
• Trell E., Oldbring J., Körsgaard R., Mattiasson I. Aryl hydrocarbon hydroxylase inducibility in carcinoma of renal pelvis and ureter. Lancet 1977; 2: 612
   Google Scholar
• Trell E., Oldbring J., Körsgaard R., Hellsten S., Mattiasson I., Telhammar E. Aryl hydrocarbon hydroxylase inducibility and carcinoma of the urinary bladder. IRCS J. Med. Set 1978; 6: 138
   Google Scholar
• Gurtoo H. L., Minowada J., Paigen B., Parker N. B., Hayner N. T. Factors influencing the measurement and the reproducibility of aryl hydrocarbon hydroxylase activity in cultured human lymphocytes. J. Nat. Cancer Inst 1977; 59: 787
   Google Scholar
• Jett J. R., Moses H. L., Branum E. L., Taylor W. F., Fontana R. S. Benzo[a]pyrene metabolism and blast formation in peripheral blood mononuclear cells from smoking and non-smoking populations and lung cancer patients. Cancer 1978; 41: 192
   PubMed Web of Science ®Google Scholar
• Lieberman J. Aryl hydrocarbon hydroxylase in bronchogenic carcinoma. N. Engl. J. Med. 1978; 298: 686
   PubMedGoogle Scholar
• Paigen B., Gurtoo H. L., Minowada J., Houten L., Vincent R., Paigen K., Parker N. B., Ward E., Hayner N. T. Questionable relation of aryl hydrocarbon hydroxylase to lung cancer risk. N. Engl. J. Med. 1977; 297: 346
   PubMed Web of Science ®Google Scholar
• Ward E., Paigen B., Steenland K., Vincent R., Minowada J., Gurtoo H. L., Sartori P., Havens M. B. Aryl hydrocarbon hydroxylase in persons with lung or laryngeal cancer. Int. J. Cancer 1979; 23: 312
   Google Scholar
• Landi M. T., Bertazzi P. A., Shields P. G., Clark G., Lucier G. W., Garte S. J., Cosma G., Caporaso N. E. Association between CYP1AI genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics 1994; 4: 242
   PubMedGoogle Scholar
• Dolwick K. M., Schmidt J. V., Carver L. A., Swanson H. I., Bradtield C. A. Cloning and expression of a human Ah receptor cDNA. Mol. Pharmacol. 1993; 44: 911
   PubMed Web of Science ®Google Scholar
• Takahashi Y., Itoh S., Shimojima T., Kamataki T. Characterization of Ah receptor promoter in human liver cell line, HepG2. Pharmacogenetics 1994; 4: 219
   Google Scholar
• Fujii-Kuriyama Y., Ema M., Matsushita N., Sogawa K. Polymorphic forms of the Ah receptor and induction of theCYP1A1 gene. Pharmacogenetics 1995; 5: S149
   Google Scholar
• Fernandez-Salguero P., Pineau T., Hilbert D. M., McPhail T., Lee S. S. T., Kimura S., Nebert D. W., Rudikoff S., Ward J. M., Gonzalez F. J. Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science 1995; 268: 722
   PubMed Web of Science ®Google Scholar
• Kimura S., Gonzalez F. J., Nebert D. W. The murine Ahlocus. Comparison of the complete cytochrome P1-450 and P2-450 cDNA nucleotide and amino acid sequences. J. Biol. Chem. 1984; 259: 10705
   PubMed Web of Science ®Google Scholar
• Bale A. E., Nebert D. W., McBride O. W. Subchromosomal localization of the dioxin-inducible P,450 locus(CYP1) and description of two RFLP's detected with a 3′P1450 cDNA probe. Cytogen. Cell Genet. 1987; 46: 574
   Google Scholar
• Kawajiri K., Nakachi K., Imai K., Yoshii A., Shinoda N., Watanabe J. Identification of genetically high risk individuals to lung cancer by polymorphisms of the cytochrome P450IA1 gene. FEBS Lett. 1990; 263: 131
   PubMed Web of Science ®Google Scholar
• Hayashi S. I., Watanabe J., Nakachi K., Kawajiri K. Genetic linkage of lung cancer-associates Msp I polymorphisms with amino acid replacement in the heme-binding region of the human cytochrome P450IA1 gene. J. Biochem. (Tokyo) 1991; 110: 407
   PubMed Web of Science ®Google Scholar
• Hayashi S. I., Watanabe J., Nakachi K., Kawajiri K. PCR detection of an A/G polymorphism within exon 7 of the CYP1A1 gene. Nucleic Acids Res. 1991; 19: 4797
   PubMed Web of Science ®Google Scholar
• Hayashi S., Watanabe J., Kawajiri K. High susceptibility to lung cancer analyzed in terms of combined genotypes of P450IA1 and Mu-class glutathione S-transferase genes. Jpn. J. Cancer Res. 1992; 83: 866
   PubMedGoogle Scholar
• Nakachi K., Imai K., Hayashi S., Kawajiri K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res. 1993; 53: 2994
   PubMed Web of Science ®Google Scholar
• Tefre T., Ryberg D., Haugen A., Nebert D. W., Skaug V., Brogger A., Borresen A. L. Human CYP1A1 (cytochrome P1450) gene: lack of association between theMsp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics 1991; 1: 20
   PubMedGoogle Scholar
• Shields P. G., Bowman E. D., Harrington A. M., Doan V. T., Weston A. Polycyclic aromatic hydrocarbon-DNA adducts in human lung and cancer susceptibility genes. Cancer Res. 1993; 53: 3486
   PubMed Web of Science ®Google Scholar
• Hirvonen A., Husgafvel-Pursiainen K., Karjalainen A., Anttila S., Vainio H. Point-mutational Mspl and Ile-Val polymorphisms closely linked in the CYP1 Al gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol. Biomark. Prev. 1992; 1: 485
   PubMed Web of Science ®Google Scholar
• Hirvonen A., Husgafvel-Pursiainen K., Anttila S., Karjalainen A., Sorsa M., Vainio H. Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer. Pharmacogenetics 1992; 2: 259
   PubMedGoogle Scholar
• Wedlund P. J., Kimura S., Gonzalez F. J., Nebert D. W. 1462V mutation in the human CYP1A1 gene: lack of correlation with either the Msp I 1.9 kb (M2) allele or CYP1 Al inducibility in a three-generation family of east Mediterranean descent. Pharmacogenetics, 4: 21, 994
   Google Scholar
• Crofts F., Cosma G. N., Currie D., Taioli E., Toniolo P., Garte S. J. A novel CYP1 Al gene polymorphism in African-Americans. Carcinogenesis 1993; 14: 1729
   PubMed Web of Science ®Google Scholar
• Taioli E., Crofts F., Trachman J., Demopoulos R., Toniolo P., Garte S. J. A specific African-AmericanCYP1A1 polymorphism is associated with adenocarcinoma of the lung. Cancer Res. 1995; 55: 472
   PubMed Web of Science ®Google Scholar
• Kelsey K. T., Wiencke J. K., Spitz M. R. A race-specific genetic polymorphism in theCYPIA1 gene is not associated with lung cancer in African-Americans. Carcinogenesis 1994; 15: 1121
   PubMed Web of Science ®Google Scholar
• London S. J., Daly A. K., Fairbrother K., Holmes C., Carpenter C. L., Navidi W. C., Idle J. R. Lung cancer risk in African-Americans in relation to a races-pecificCYPIAI polymorphism. Cancer Res. 1995; 55: 6035
   PubMed Web of Science ®Google Scholar
• Taioli E., Trachman J., Chen X., Toniolo P., Garte S. J. ACYPIAI restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Res. 1995; 55: 3757
   PubMed Web of Science ®Google Scholar
• Mahgoub A., Idle J. R., Dring L. G., Lancaster R., Smith R. L. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2: 584
   PubMed Web of Science ®Google Scholar
• Gonzalez F. J., Meyer U. A. Molecular genetics of the debrisoquine-sparteine polymorphism. Clin. Pharmacol. Ther. 1991; 50: 233
   PubMed Web of Science ®Google Scholar
• Johansson I., Oscarson M., Yue Q. Y., Bertilsson L., Sjoqvist F., Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol 1994; 46: 452
   PubMed Web of Science ®Google Scholar
• Bertilsson L., Lou Y. Q., Dy Y. L., Liu Y., Kuang T. Y., Liao X. ML, Wang K. Y., Reviriego J., Iselius L., Sjöqvist F. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin. Pharmacol. Ther. 1992; 51: 388
   PubMed Web of Science ®Google Scholar
• Mannervik B., Awasthi Y. C., Board P. G., Hayes J. D., Di Hio C., Ketterer B., Listowsky I., Morgenstern R., Muramatsu M., Pearson W. R., et al. Nomeclature for human glutathione transferases. Biochem. J. 1992; 282: 305
   PubMed Web of Science ®Google Scholar
• Buchert E. T., Woosley R. L. Clinical implications of variable antiarrhythmic drug metabolism. Pharmacogenetics 1992; 2: 2
   PubMedGoogle Scholar
• Nebert D. W. Polymorphism of human CYP2D genes involved in drug metabolism: possible relationship to individual cancer risk. Cancer Cells 1991; 3: 93
   Google Scholar
• Gonzalez F. J., Idle J. R. Pharmacogenetic phenotyping and genotyping: present status and future potential. Clin. Pharmacokinet. 1994; 26: 59
   PubMed Web of Science ®Google Scholar
• Caporaso N., DeBaun M. R., Rothman N. Lung cancer andCYP2D6 (the debrisoquine polymorphism): sources of heterogeneity in the proposed association. Pharmacogenetics 1995; 5: S129
   Google Scholar
• Steen V., Andreassen O. A., Daly A. K., Tefre T., Borresen A. L., Idle J. R., Gulbrandsen A. K. Detection of the poor metabolizer-associatedCYP2D6(D) gene deletion allele by long-PCR methodology. Pharmacogenetics 1995; 5: 215
   PubMedGoogle Scholar
• Meyer U. A. Pharmacogenetics: the slow, the rapid and the ultrarapid. Proc. Natl. Acad. Sci. U.S.A. 1994; 91: 1983
   PubMed Web of Science ®Google Scholar
• Barbeau A. E., Cloutier T., Roy M., Plasse L., Paris S., Poirier J. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet 1985; 2: 1213
   PubMed Web of Science ®Google Scholar
• Poirier J., Roy M., Campanella G., Cloutier T., Paris S. Debrisoquine metabolism in Parkinsonian patients treated with antihistamine drugs. Lancet 1987; 2: 386
   Google Scholar
• Steventon G. B., Heathfield M. T. E., Waring R. H., Williams A. C. Xenobiotic metabolism in Parkinson's disease. Neurology 1989; 39: 883
   PubMed Web of Science ®Google Scholar
• Steiger M. J., Lledo P., Quinn N. P., Marsden C. D., Turner P., Jenner P. G. Debrisoquine hydroxylation in Parkinson's disease. Acta Neurol Scand 1992; 86: 159
   Google Scholar
• Gudjonsson O., Sanz E., Alvan G., Aquilonius S. M., Reviriego J. Poor hydroxylator pheno-types of debrisoquine are not overrepresented in a group of patients with Parkinson's disease. Br. J. Clin. Pharmacol 1990; 30: 301
   Google Scholar
• Kallio J., Martilli R. J., Rinne U. K., Sonninen V., Syvälathi E. Debrisoquine oxidation in Parkinson's disease. Acta Neurol. Scand. 1991; 83: 194
   PubMed Web of Science ®Google Scholar
• Kondo I., Kanazawa I. Debrisoquine hydroxylase and Parkinson's disease. Adv. Neurol. 1993; 60: 338
   Google Scholar
• Armstrong M., Daly A. K., Cholerton S., Bateman D. N., Idle J. R. Mutant debrisoquine hydroxy-lation genes in Parkinson's disease. Lancet 1992; 339: 1017
   PubMed Web of Science ®Google Scholar
• Smith C. A. D., Gough A. C., Leigh P. N., Summers B. A., Harding A. E., Maranganore D. M., Sturman S. G., Schapira A. H. V., Williams A. C., Spurr N. K., et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992; 339: 1375
   PubMed Web of Science ®Google Scholar
• Tyndale R. F., Sunahara R., Inaba T., Kalow W., Gonzalez F. J., Niznik H. B. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol. Pharmacol 1991; 40: 63
   PubMed Web of Science ®Google Scholar
• Sindrup S. H., Poulsen L., Brosen K., Arendt-Nielsen L., Gram L. F. Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?. Pain 1993; 53: 335
   PubMed Web of Science ®Google Scholar
• Sindrup S. H., Brosen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 1995; 5: 335
   PubMedGoogle Scholar
• Ayesh R., Idle J. R., Ritchie J. C., Crothers M. J., Hetzel M. R. Metabolic oxidation pheno-types are markers for susceptibility to lung cancer. Nature, (London) 1984; 312: 169
   PubMed Web of Science ®Google Scholar
• Roots I., Drakoulis N., Bröckmoller J. Polymorphic enzymes and cancer risk: concepts, methodology and data review. Pharmacogenetics of Drug Metabolism, W. Kalow. Pergamon Press, New York 1992; 815
   Google Scholar
• Ingelman-Sundberg M., Johansson I., Persson I., Yue Q. Y., Dahl M. L., Bertilsson L., Sjöqvist F. Genetic polymorphism of cytochromes P450: in-terethnic differences and relationship to incidence of lung cancer. Pharmacogenetics 1992; 2: 264
   PubMedGoogle Scholar
• Caporaso N. E., Tucker M. A., Hoover R. N., Hayes R. B., Pickle L. W., Issaq H. J., Muschik G. M., Green-Gallo L., Buivys D., Aisner S., et al. Lung cancer and the debrisoquine metabolic phe-notype. J. Natl. Cancer Inst. 1990; 82: 1264
   PubMed Web of Science ®Google Scholar
• Cholerton S., Arpanahi A., McCracken N., Boustead C., Taber H., Johnstone E., Leathart J., Daly A. K., Idle J. R. Poor metabolisers of nicotine andCYP2D6 polymorphism. Lancet 1994; 343: 62
   PubMed Web of Science ®Google Scholar
• Koop D. R. Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB J. 1992; 6: 724
   PubMed Web of Science ®Google Scholar
• Snawder J. E., Roe A. L., Benson R. W., Casciano D. A., Roberts D. W. Cytochrome P450-depen-dent metabolism of acetaminophen in four human transgenic lymphoblastoid cell lines. Pharmacogenetics 1994; 4: 43
   PubMedGoogle Scholar
• Guengerich F. P., Kim D. H., Iwasaki M. Role of human P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol 1991; 4: 168
   PubMed Web of Science ®Google Scholar
• Guengerich F. P. Polymorphism of cytochrome P-450 in humans. Trends Pharmacol. Set 1989; 10: 107
   PubMed Web of Science ®Google Scholar
• Daly A. K., Cholerton S., Armstrong M., Idle J. R. Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility. Environ. Health Perspect. 1994; 102(Suppl. 9)55
   PubMedGoogle Scholar
• McBride O. W., Umeno M., Gelboin H. V., Gonzalez F. J. Taq I polymorphism in the human P450IIE1 gene on chromosome 10 (CYP2E), Nucleic Acids Res. 1987; 15: 10071
   PubMed Web of Science ®Google Scholar
• Uematsu F., Kikuchi H., Ohmachi T., Sagami I., Motomiya M., Kamataki T., Komori M., Watanabe M. Two common RFLPs of theCYP2E gene. Nucleic Acids Res. 1991; 19: 2803
   PubMedGoogle Scholar
• Hayashi S., Watanabe J., Kawajiri K. Genetic polymorphisms in the 5'-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J. Biochem. 1991; 110: 559
   PubMed Web of Science ®Google Scholar
• Watanabe J., Hayashi S. L, Nakachi K., Imai K., Suda Y., Sekine T., Kawajiri K. Pst I andRsa I RFLP in complete linkage disequilibrium at theCYP2E1 gene, Nucleic Acids Res. 1990; 18: 7194
   PubMedGoogle Scholar
• Stephens E. A., Taylor J. A., Kaplan N., Yang C. H., Hsieh L. L., Lucier G. W., Bell D. A. Ethnic variation in theCYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics 1994; 4: 185
   PubMedGoogle Scholar
• Uematsu F., Kikuchi H., Motomiya M., Abe T., Sagami I., Ohmachi T., Wakui A., Kanamaru R., Watanabe M. Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn. J. Cancer Res. 1991; 82: 254
   PubMedGoogle Scholar
• Persson I., Johansson I., Bergling H., Dahl M. L., Seidegard J., Rylander R., Rannug A., Hogberg J., Ingelman-Sundberg M. Genetic polymorphism of cytochrome P4502E1 in a Swedish population: relationship to lung cancer. FEBS Lett. 1993; 319: 207
   PubMed Web of Science ®Google Scholar
• Uematsu F., Ikawa S., Kikuchi H., Sagami I., Kanamaru R., Abe T., Satoh K., Motomiya M., Watanabe M. Restriction fragment length polymorphism of the humanCYP2E1 (cytochrome P450IIE1) gene and susceptibility to lung cancer: possible relevance to low smoking exposure. Pharmacogenetics 1994; 4: 58
   PubMedGoogle Scholar
• Tsutsumi M., Lasker J. M., Shimizu M., Rosman A. S., Lieber C. S. The intralobular distribution of ethanol-inducible P450IIE1 in rat and human liver. Hepatology 1989; 10: 437
   PubMed Web of Science ®Google Scholar
• Wrighton S. A., Thomas P. E., Molowa D. T., Haniu M., Shively J. F., Maines S. L., Watkins P. B., Parker G., Mendez-Picon G., Levin W., et al. Characterization of ethanol-inducible human liverN-nitrosodimethylamine demethylase. Biochemistry 1986; 25: 6371
   Google Scholar
• Takahashi T., Lasker J. M., Rosman A. S., Lieber C. S. Induction of cytochrome P-4502E1 in the human liver by ethanol is caused by a corresponding increase of encoding mRNA. Hepatolagy 1992; 17: 236
   Google Scholar
• Peterson F. J., Holloway D. E., Erickson R. R., Duquette P. H., McClain C. J., Holtzman J. L. Ethanol induction of acetaminophen toxicity and metabolism. Life Sci. 1980; 37: 1705
   Google Scholar
• Lucas D., Ménez C., Girre C., Berthou F., Bodénez P., Joannet I., Hispard E., Bardou L. G., Ménez J. F. CytochromeP450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic-Caucasian subjects. Pharmacogenetics 1995; 5: 298
   PubMedGoogle Scholar
• Ayesh R., Mitchell S. C., Smith R. L. Body malodour syndromes. Lancet 1995; 345: 1308
   Google Scholar
• Ayesh R., Mitchell S. C., Zhang A., Smith R. L. The fish odour syndrome: biochemical, familial. and clinical aspects. BMJ 1993; 307: 655, (see comments)
   PubMed Web of Science ®Google Scholar
• Dolphin C., Shephard E. A., Povey S., Palmer C. N., Ziegler D. M., Ayesh R., Smith R. L., Phillips I. R. Cloning, primary sequence, and chromosomal mapping of a human flavin-containing monooxygenase (FMOD.i. Biol. Chem. 1991; 266: 12379
   Google Scholar
• Grant D M. Molecular genetics of the N-acetyl-transferases. Pharmacogenetics 1993; 3: 45
   PubMedGoogle Scholar
• Lawton M. P., Philpot R. M. Molecular genetics of the flavin-dependent monooxygenases. Pharmacogenetics 1993; 3: 40
   PubMedGoogle Scholar
• Hines R. N., Cashman J. R., Philpot R. M., Williams D. E., Ziegler D. M. The mammalian flavin-containing monooxygenases: molecular characterization and regulation of expression. Toxicol. Appl. Pharmacol. 1994; 125: 1
   PubMed Web of Science ®Google Scholar
• Seidegard J., DePierre J. Microsomal epoxide hydrolase properties, regulation and function. Biochim. Biophys. Acta 1983; 695: 251
   PubMed Web of Science ®Google Scholar
• Farin F. M., Omiecinski C. J. Regiospecific expression of cytochrome P-450s and microsomal epoxide hydrolase in human brain tissue. J. Toxicol. Environ. Health 1993; 40: 317
   PubMed Web of Science ®Google Scholar
• Farin F. M., Pohlman T. H., Omiecinski C. J. Expression of cytochrome P450s and microsomal epoxide hydrolase in primary cultures of human umbilical vein endothelial cells. Toxicol. Appl. Pharmacol. 1994; 124: 1
   PubMed Web of Science ®Google Scholar
• Heckbert S. R., Weiss N. S., Hornung S. K., Eaton D. L., Motulsky A. G. Glutathione-S-trans-ferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers. J. Natl. Cancer Inst. 1992; 84: 414
   PubMed Web of Science ®Google Scholar
• Gaedigk A., Spielberg S. P., Grant D. M. Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions. Pharmacogenetics 1994; 4: 142
   PubMedGoogle Scholar
• Hassett C., Aicher L., Sidhu J. S., Omiecinski C. J. Human microsomal epoxide hydrolase: genetic polymorphism and functional expressionin vitro of amino acid variants. Hum. Mol. Genet. 1994; 3: 421
   PubMed Web of Science ®Google Scholar
• McGlynn K. A., Rosvold E. A., Lustbader E. D., Hu Y., Clapper M. L., Zhou T., Wild C. P., Xia X. L., Baffoe-Bonnie A., Ofori-Adjei D., et al. Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B. Proc. Natl. Acad. Sci. U.S.A. 1995; 92: 2384
   PubMed Web of Science ®Google Scholar
• Lind C., Cadenas E., Hochstein P., Ernster L. DT-Diaphorase: purification, properties and function. Methods Enzymoi 1990; 186: 287
   PubMed Web of Science ®Google Scholar
• Jaiswal A. K. Human NAD(P)H: quinone oxy-doreductase (NQOI) gene structure and induction by dioxin. Biochemistry 1991; 30: 10647
   PubMed Web of Science ®Google Scholar
• Jaiswal A. K., McBride O. W., Adesnik M., Nebert D. W. Human dioxin-inducible cytosolic NAD(P)H:menadione oxidoreductase. J. Biol. Chem. 1988; 263: 13572
   PubMed Web of Science ®Google Scholar
• Traver R. D., Tetsuro H., Danenberg K. D., Stadlbauer T. H. W., Danenberg P. V., Ross D., Gibson N. W. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mytomycin sensitivity. Cancer Res. 1995
   Google Scholar
• Rosvold E. A., McGlynn K. A., Lustbader E. D., Buetow K. H. Identification of an NAD(P)H:qui-none oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics 1995; 5: 199
   PubMedGoogle Scholar
• Jim C. J., Miners J. O., Burchell B., Mackenzie P. I. The glucuronidation of hydroxylated metabolites of benzo[a]pyrene and 2-acetylaminofluorene by cDNA-expressed human UDP glucuronosyltrans-ferases. Carcinogenesis 1993; 14: 2637
   Google Scholar
• Moghrabi N., Clarke D. J., Burchell B., Boxer M. Cosegregation of intragenic markers with a novel mutation that causes Crigler-Najjar type I: implication in carrier detection and prenatal diagnosis. Am. J. Hum. Genet. 1993; 53: 722
   PubMed Web of Science ®Google Scholar
• Patel M., Tang B. K., Kalow W. (S)Oxazepam glucuronidation is inhibited by ketoprofen and other substrates of UGT2B7. Pharmacogenetics 1995; 5: 43
   PubMedGoogle Scholar
• Bonicke R., Reif W. Enzymatic inactivation of isonicotinic acid hydrazide in humans and animals. Arch. Exp. Pathol. Pharmakol. 1953; 220: 321
   PubMedGoogle Scholar
• Bonicke R., Lisboa B. P. On the inherited basis of intraindividual constancy of isoniazid elimination in man (studies of monozygotic and dizygotic twins). Naturwissenschaften 1957; 44: 314
   Web of Science ®Google Scholar
• Weber W. W., Hein D. W. N-acetylation pharmacogenetics. Pharmacol. Rev. 1985; 37: 25
   PubMed Web of Science ®Google Scholar
• Hickman D., Sim E. N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans. Biochem. Pharmacol 1991; 42: 1007
   PubMed Web of Science ®Google Scholar
• Blum M., Grant D. M., McBride O. W., Heim M., Meyer U. A. Human arylamine N-acetyl-transferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol. 1990; 9: 193
   PubMed Web of Science ®Google Scholar
• Ohsako S., Deguchi T. Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver. J. Biol. Chem. 1990; 265: 4630
   PubMed Web of Science ®Google Scholar
• Ebisawa T., Deguchi T. Structure and restriction fragment length polymorphism of genes for human liver arylamine N-acetyltransferase. Biochem. Biophys. Res. Commun. 1991; 177: 1252
   PubMed Web of Science ®Google Scholar
• Bell D. A., Taylor J. A., Butler M. A., Stephens E. A., Wiest J., Brubacker L. H., Kadlnbar F. F., Lucier G. W. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new acetylator allele common in African-Americans. Carcinogenesis 1993; 14: 1689
   PubMed Web of Science ®Google Scholar
• Abe M., Deguchi T., Suzuki T. The structure and characteristics of a fourth allele of polymorphic n-acetyltransferase gene found in the Japanese population. Biochem. Biophys. Res. Commun. 1993; 191: 811
   PubMed Web of Science ®Google Scholar
• Vatsis K. P., Weber W. W., Bell D. A., Dupret J. M., Evans D. A. P., Grant D. M., Hein D. W., Lin H. J., Meyer U. A., Relling M. V., et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995; 5: 1
   PubMedGoogle Scholar
• Rothman N., Hayes R. B., Bi W., Caporaso N., Broly F., Woosley R. L., Yin S., Feng P., You X., Meyer U. A. Correlation between N-acetyltransferase activity and NAT2 genotype in Chinese males. Pharmacogenetics 1993; 3: 250
   PubMedGoogle Scholar
• Cascorbi I., Drakoulis N., Brockmtiller J., Maurer A., Sperling K., Roots I. Arylamine N-acetyltransferase(NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am. J. Hum. Genet. 1995; 57: 581
   PubMed Web of Science ®Google Scholar
• Cartwright R. A. Epidemiological studies on N-acetylation and C-center ring oxidation in neoplasia. Genetic Variability in Responses to Chemical Exposure, G. S. Omenn, H. V. Gelboin. Cold Spring Harbor Laboratory, New York 1984; 359
   Google Scholar
• Karakaya A. E., Cok I., Sardas S., Gogus O. S. N-Acetyltransferase phenotype of patients with bladder cancer. Hum. Toxicol 1989; 5: 333
   Google Scholar
• Hayes R., Bi W., Rothman N., Broly F., Caporaso N., Feng P., You X., Yin S., Woosley R. L., Meyer U. A. N-Acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. Carcinogenesis 1993; 14: 675
   PubMed Web of Science ®Google Scholar
• Lang N. P., Butler M. A., Massengill J. P., Lawson M., Stotts R. C., Hauer-Jensen M., Kadlubar F. F. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol. Biomark. Prev. 1994; 3: 675
   PubMed Web of Science ®Google Scholar
• Vatsis K. P., Martell K. J., Weber W. W. Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc. Natl. Acad. Sci. U.S.A. 1991; 88: 6333
   PubMed Web of Science ®Google Scholar
• Weber W. W., Vatsis K. P. Individual variability in p-aminobenzoic acid N-acetylation by human /V-acetyltransferase (NAT 1) or peripheral blood. Pharmacogenetics 1993; 3: 209
   PubMedGoogle Scholar
• Bell D. A., Badawi A. F., Lang N. P., Ilett K. F., Kadlubar F. F., Hirvonen A. Polymorphism in the N-acetyltransferase 1(NAT1) polyadenylation signal: association ofNAT110 allele with higherN-acetylation activity in bladder and colon tissue. Cancer Res. 1995; 55: 5226
   PubMed Web of Science ®Google Scholar
• Badawi A. F., Hirvonen A., Bell D. A., Lang N. P., Kadlubar F. F. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res. 1995; 55: 5230
   PubMed Web of Science ®Google Scholar
• Bell D. A., Stephens E. A., Castranio T., Umbach D. M., Watson M., Deakin M., Elder J., Hendrickse C., Duncan H., Strange R. C. Polyadenylation polymorphism in the acetyltransferase I gene(NAT]) increases risk of colorectal cancer. Cancer Res. 1995; 55: 3537
   PubMed Web of Science ®Google Scholar
• Hein D. W., Doll M. A., Rustan T. D., Gray K., Feng Y., Ferguson R. J., Grant D. M. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 1993; 14: 1633
   PubMed Web of Science ®Google Scholar
• Vineis P., Bartsch H., Caporaso N., Harrington A. M., Kadlubar F. F., Landi M. T., Malaveille C., Shields P. G., Skipper P., Talaska G., et al. Genetically-based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature (London) 1994; 369: 154
   PubMed Web of Science ®Google Scholar
• Daniel V. Glutathione S-transferases: gene structure and regulation of expression. Crit. Rev. Biochem. Mol. Biol 1993; 28: 173
   PubMed Web of Science ®Google Scholar
• Mannervik B., Danielson U. H. Glutathione transferases – structure and catalytic activity. CRC Crit. Rev. Biochem. 1988; 23: 281
   Google Scholar
• Awasthi Y. C., Sharma R., Singhal S. S. Human glutathione S-transferases. Int. J. Biochem. 1994; 26: 295
   PubMedGoogle Scholar
• Zhong S., Wyllie A. H., Barnes D., Wolf C. R., Spurr N. K. Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis 1993; 14: 1821
   PubMed Web of Science ®Google Scholar
• Fryer A. A., Zhao L., Alldersea J., Pearson W. R., Strange R. C. Use of site-directed mutagenesis of allele-specific PCR primers to identify the GSTM1 A, GSTM1 B, GSTM1 A,B and GSTM1 null polymorphisms at the glutathione S-transferase, GSTM1 locus. Biochem. J. 1993; 295: 313
   PubMed Web of Science ®Google Scholar
• Bell D. A., Taylor J. A., Paulson D. F., Robertson C. N., Mohler J. L., Lucier G. W. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-trans-ferase Ml (GSTM1) that increases susceptibility to bladder cancer. J Natl. Cancer Inst. 1993; 85: 1159
   PubMed Web of Science ®Google Scholar
• Nakajima T., Elovaara E., Anttila S., Hirvonen A., Camus A. M., Hayes J. D., Ketterer B., Vainio H. Expression and polymorphism of glutathione S-transferase in human lungs: risk factors in smoking-related lung cancer. Carcinogenesis 1995; 16: 707
   PubMed Web of Science ®Google Scholar
• Fryer A. A., Zhao L., Alldersea J., Boggild M. D., Perrett C. W., Clayton R. N., Jones P. W., Strange R. C. The glutathione S-transferases: polymerase chain reaction studies on the frequency of the GSTM1 0 genotype in patients with pituitary adenomas. Carcinogenesis 1993; 14: 563
   PubMed Web of Science ®Google Scholar
• Anttila S., Hirvonen A., Husgafvel-Pursiainen K., Karjalainen A., Nurminen T., Vainio H. Combined effect of CYP1A1 inducibility andGSTMl polymorphism on histological type of lung cancer. Carcinogenesis 1994; 15: 1133
   PubMed Web of Science ®Google Scholar
• Hirvonen A., Husgafvel-Pursiainen K., Anttila S., Vainio H. The GSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung. Carcinogenesis 1993; 14: 1479
   PubMed Web of Science ®Google Scholar
• Ketterer B., Harris J. M., Talaska G., Meyer D. J., Pemble S. E., Taylor J. B., Lang N. P., Kadlubar F. F. The human glutathione S-transferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer. Em: Health Perspect. 1992; 98: 87
   PubMed Web of Science ®Google Scholar
• London S. J., Daly A. K., Cooper J., Navidi W. C., Carpenter C. L., Idle J. R. Polymorphism of glutathione S-transferase Ml and lung cancer risk among African-Americans and Caucasians in Los Angeles county, California. J. Natl. Cancer Inst. 1995; 87: 1246
   PubMed Web of Science ®Google Scholar
• Trizna Z., Dayman G., Spitz M. R., Briggs K. L., Goepfert H. Glutathione S-transferase genotypes as risk factors for head and neck cancer. Am. J. Surgery 1995; 170: 499
   PubMed Web of Science ®Google Scholar
• Heagerty A. H. M., Fitzgerald D., Smith A., Bowers B., Jones P., Fryer A. A., Zhao L., Alldersea J., Strange R. C. Glutathione S-transferase GSTM1 phenotypes and protection against cutaneous tumours. Lancet 1994; 343: 266
   PubMed Web of Science ®Google Scholar
• Lafuente A., Molina R., Palou J., Castel T., Moral A., Trias M., MMM Group. Pheno-type of glutathione S-transferase Mu (GSTM1) and susceptibility to malignant melanoma. Br. J. Cancer. 1995; 72: 324
   PubMedGoogle Scholar
• Lin H. J., Han C. Y., Bernstein D. A., Hsiao W., Lin B. K., Hardy S. Ethnic distribution of the glutathione transferase Mu 1–1(GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis 1994; 15: 1077
   PubMed Web of Science ®Google Scholar
• Nakachi K., Imai K., Hayashi S. L, Kawajiri K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res. 1993; 53: 2994
   PubMed Web of Science ®Google Scholar
• Kawajiri K., Watanabe J., Eguchi H., Hayashi S. L. Genetic polymorphisms of drug-metabolizing enzymes and lung cancer susceptibility. Pharmacogenetics 1995; 5: S70
   PubMedGoogle Scholar
• Kihara M., Kihara M., Noda K. Lung cancer-risk of GSTM1 null genotype is dependent on the extent of tobacco smoke exposure. Carcinogenesis 1994; 15: 415
   PubMed Web of Science ®Google Scholar
• Kihara M., Noda K., Kihara M. Distribution of GSTM1 null genotype in relation to gender, age and smoking status in Japanese lung cancer patients. Pharmacogenetics 1995; 5: S74
   Google Scholar
• Hirvonen A., Nylund L., Kociba P., Husgafvel-Pursiainen K., Vainio H. Modulation of urinary mutagenicity by genetically determined carcinogen metabolism in smokers. Carcinogenesis 1994; 15: 813
   PubMed Web of Science ®Google Scholar
• Anttila S., Luostarinen L., Hirvonen A., Elovaara E., Karjalainen A., Nurminen T., Hayes J. D., Vainio H., Ketterer B. Pulmonary expression of glutathione S-transferase M3 in lung cancer patients: association withGSTM I polymorphism, smoking, and asbestos exposure. Cancer Res. 1995; 55: 3305
   PubMed Web of Science ®Google Scholar
• Pemble S., Schroeder K. R., Spencer S. R., Meyer D. J., Hallier E., Bolt H. M., Ketterer B., Taylor J. B. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterisation of a genetic polymorphism. Biochem. J. 1994; 300: 271
   PubMed Web of Science ®Google Scholar
• Elexpuru-Camiruaga J., Buxton N., Kandula V., Dias P., Campbell D., McIntosh J., Broome J., Jones P., Inskip A., Alldersea J., et al. Susceptibility to astrocytoma and meningioma: influence of allelism at glutathione S-transferase (GSTT1 and GSTM 1) and cytochrome P-450 (CYP2D6) loci. Cancer Res. 1995; 55: 4237
   Google Scholar
• Warwick A., Sarhanis P., Redman C., Pemble S., Taylor J. B., Ketterer B., Jones P., Alldersea J., Gilford J., Yengi L., et al. Theta class glutathione S-transferase GSTT1 genotypes and susceptibility to cervical neoplasia: interactions with GSTM 1, CYP2D6 and smoking. Carcinogenesis 1994; 15: 2841
   PubMed Web of Science ®Google Scholar
• Butler M. A., Iwasaki M., Guengerich F. P., Kadlubar F. F. Human P450PA (P-450–1A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxida-tion of carcinogenic amines. Proc. Natl. Acad. Sci. U.S.A. 1989; 86: 7696
   PubMed Web of Science ®Google Scholar
• Crespi C. L., Penman B. W., Gelboin H. V., Gonzalez F. J. A tobacco smoke-derived nitrosamine. 4-(methylnitrosamino)-l-(3-pyridyl)-l-butanone, is activated by multiple cytochrome P450s including the polymorphic cytochrome P4502D6. Carcinogenesis 1991; 12: 1197
   PubMed Web of Science ®Google Scholar
• Ikeya K., Jaiswal A. K., Owens R. A., Jones J. E., Nebert D. W., Kimura S. HumanCYP1A2. Sequence, gene structure, comparison with the mouse and rat orthologous gene, and genetic differences in liver 1A2 mRNA concentrations. Mol. Endocrinol 1989; 3: 1399
   PubMed Web of Science ®Google Scholar
• Yamazaki H., Mimura M., Oda Y., Inui Y., Shiraga T., Iwasaki K., Guengerich F. P., Shimada T. Roles of different forms of cytochrome P450 in the activation of the promutagen 6-aminochry-sene to genotoxic metabolites in human liver microsomes. Carcinogenesis 1993; 14: 1271
   PubMed Web of Science ®Google Scholar
• Kadlubar F. F., Butler M. A., Kaderlik K. R., Chou H. C., Lang N. P. Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. Environ. Health Perspect. 1992; 98: 69
   PubMed Web of Science ®Google Scholar
• Shimada T., Yun C. H., Hiroshi Y., Gautier J. C., Beaune P. H., Guengerich F. P. Characterization of human lung microsomal cytochrome P4501 Al and its role in the oxidation of chemical carcinogens. Mol. Pharmacol 1992; 41: 856
   PubMed Web of Science ®Google Scholar
• Butler M. A., Lang N. P., Young J. F., Caporaso N. E., Vineis P., Hayes R. B., Teitel C. H., Massengill J. P., Lawsen M. F., Kadlubar F. F. Determination of CYP1A2 and acetyltransferase phenotype in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2: 116
   PubMedGoogle Scholar
• Kapitulnik J., Poppers P. J., Conney A. H. Comparative metabolism of benzo(a)pyrene and drugs in human liver. Clin. Pharmacol. Ther. 1977; 21: 166
   PubMed Web of Science ®Google Scholar
• Miles J. S., McLaren A. W., Forrester L. M., Glancey M. J., Lang M. A., Wolf C. R. Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochem. J. 1990; 267: 365
   PubMed Web of Science ®Google Scholar
• Yamano S., Tatsuno J., Gonzalez F. J. TheCYP2A3 gene product catalyzes coumarin 7-hydroxy-lation in human liver microsomes. Biochemistry 1990; 29: 1322
   PubMed Web of Science ®Google Scholar
• Maurice M., Emiliani S., Dalet-Beluche I., Derancourt J., Lange R. Isolation and characterization of a cytochrome P-450 of the IIA subfamily from human liver microsomes. Eur. J. Biochem. 1991; 200: 365
   Google Scholar
• Fernandez-Salguero P., Hoffman S. M. G., Cholerton S., Mohrenweiser H., Raunio H., Rautio A., Pelkonen O., Huang J. D., Evans W. E., Idle J. R., et al. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the humanCYP2A genes and identification of variantCYP2A6 alleles. Am. J. Hum. Genet. 1995; 57: 651
   PubMed Web of Science ®Google Scholar
• Ding X., Coon M. J. Purification and characterization of two unique forms of cytochrome P450 from rabbit nasal microsomes. Biochemistry 1988; 27: 8330
   PubMed Web of Science ®Google Scholar
• Fernandez-Salguero P., Gonzalez F. J. TheCYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. Pharmacogenetics 1995; 5: SI23
   Google Scholar
• Bale A. E., Mitchell A. L., Gonzalez F. J., McBride O. W. Localization ofCYP2F1 by multipoint linkage analysis and pulse-field gel electrophoresis. Genomics 1991; 10: 284
   Google Scholar
• Ged C., Umbenhauer D. R., Bellew T. M., Bork R. W., Srivastava P. K., Shinriki N., Lloyd R. S., Guengerich F. P. Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4'-hydroxy-lase. Biochemistry 1988; 27: 6929
   PubMed Web of Science ®Google Scholar
• Inoue K., Inazawa J., Suzuki Y., Shimada T., Yamazaki H., Guengerich F. P., Abe T. Fluorescence in situ hybridization analysis of chromosomal localization of three human cytochrome P450 2C genes (CYP2C8, 2C9, and 2C10) at 10q24.1. Jpn. J. Hum. Genet. 1994; 39: 337
   PubMedGoogle Scholar
• Kupfer A., Preisig R. Pharmacogenetics of mephenytoin: new drug hydroxylation polymorphism in man. Eur. J. Clin. Pharmacol 1984; 26: 753
   PubMed Web of Science ®Google Scholar
• Goldstein J. A., Faletto M. B., Romkes-Sparks M., Sullivan T., Kitareewan S., Raucy J. L., Lasker J. M., Ghanayem B. I. Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxy-lase in humans. Biochemistry 1994; 33: 1743
   PubMed Web of Science ®Google Scholar
• de Morais S. M., Wilkinson G. R., Blaisdell J., Nakamura K., Meyer U. A., Goldstein J. A. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol Chem. 1994; 269: 15419
   PubMed Web of Science ®Google Scholar
• Wrighton S. A., Stevens J. C., Becker G. W., YandenBranden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. Arch. Biochem. Biophys. 1993; 306: 240
   PubMed Web of Science ®Google Scholar
• Goldstein J. A., de Morais S. M. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4: 285
   PubMedGoogle Scholar
• Brockmoller J., Rost K. L., Gross D., Schenkel A., Roots I. Phenotyping of CYP2C19 with enantio-specific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G-A-splice site mutation. Pharmacogenetics 1995; 5: 80
   PubMedGoogle Scholar
• Adedoyin A., Prakash C., O'Shea D., Blair I. A., Wilkinson G. R. Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects. Pharmacogenetics 1994; 4: 27
   PubMedGoogle Scholar
• Yasumori T., Li Q. H., Yamazoe Y., Ueda M., Tsuzuki T., Kato R. Lack of low Km diazepam N-demethylase in livers of poor metabolizers for S-mephenytoin 4'-hydroxylation. Pharmacogenetics 1994; 4: 323
   PubMedGoogle Scholar
• Yasumori T., Nagata K., Yang S. K., Chen L. S., Murayama N., Yamazoe Y., Kato R. Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. Pharmacogenetics 1993; 3: 291
   PubMedGoogle Scholar
• Cresteil T., Monsarrat B., Alvinerie P., Treluyer J. M., Vieira I., Wright M. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res. 1994; 54: 386
   PubMed Web of Science ®Google Scholar
• Rahman A., Korzekwa K. R., Grogan J., Gonzalez F. J., Harris J. W. Selective biotransformation of taxol to 6a-hydrotaxol by human cytochrome P450 2C8. Cancer Res. 1994; 54: 5543
   PubMed Web of Science ®Google Scholar
• Watkins P. B. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994; 4: 171
   PubMedGoogle Scholar
• Breimer D. D., Schellens J. M. H., Soons P. A. Nifepidine: variability in its kinetics and metabolism in man. Pharmacol. Ther. 1989; 44: 445
   Google Scholar
• Fleming C. M., Branch R. A., Wilkinson G. R., Guengerich F. P. Human liver microsomal N-hydroxylation of dapsone by cytochrome P4503A4. Mol Pharmacol. 1992; 41: 975
   PubMed Web of Science ®Google Scholar
• Watkins P. B., Murray S. A., Winkelman L. G., Heuman D. M., Wrighton S. A., Guzelian P. S. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochrome P450. J. Clin. Invest. 1989; 83: 688
   PubMed Web of Science ®Google Scholar
• Kolars J. C., Lown K. S., Schmiedlin-Ren P., Ghosh M., Fang C., Wrighton S. A., Merion R. M., Watkins P. B. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994; 4: 247
   PubMedGoogle Scholar
• Daly A. K., Salh B. S., Bilton D., Allen J., Knight A. D., Webb A. K., Braganza J. M., Idle J. R. Deficient nifepidine oxidation: a rare inherited trait associated with cystic fibrosis kindreds. Pharmacogenetics 1992; 2: 19
   PubMedGoogle Scholar
• Furlong C. E., Costa L. G., Hassett C., Richter R. J., Sundstrom J. A., Adler D. A., Disteche C. M., Omiecinski C. J., Chapline C., Crabb J. W. Human and rabbit paraoxonases: purification. cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification. Chem. Biol. Interact. 1993; 87: 35
   PubMed Web of Science ®Google Scholar
• Tsui L. C., Buchwald M., Barker D., Braman J. C., Knowlton R., Schumm J. W., Eiberg H., Mohr J., Kennedy D., Plavsic N. Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker. Science 1985; 230: 1054
   PubMed Web of Science ®Google Scholar
• Knowlton R. G., Cohen-Haguenauer O., Van Cong N., Frezal J., Brown V. A., Barker D., Braman J. C., Schumm J. W., Tsui L. C., Buchwald M. A polymorphic DNA marker linked to cystic fibrosis is located on chromosome 7. Nature, (London) 1985; 318: 380
   Web of Science ®Google Scholar
• Adkins S., Gan K. N., Mody M., La Du B. N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am. J. Hum. Genet 1993; 52: 598
   PubMed Web of Science ®Google Scholar
• Karakaya A., Suzen S., Sardas S., Karakaya A. E., Vural N. Analysis of the serum paraoxonase/arylesterase polymorphism in a Turkish population. Pharmacogenetics 1991; 1: 58
   Google Scholar
• Roy A. C., Saha N., Tay J. S., Ratnam S. S. Serum paraoxonase in three populations of Southeast Asia. Hum. Hered. 1991; 41: 265
   PubMed Web of Science ®Google Scholar
• Clavel J., Hemon D. Fundamentals of case-control studies. Pharmacogenetics 1993; 3: 160
   Google Scholar
• Lander E. S., Schork N. J. Genetic dissection of complex traits. Science 1994; 265: 2037
   PubMed Web of Science ®Google Scholar
• Lifton R. P., Jeunemaitre X. Finding genes that cause human hypertension. J. Hypertens. 1993; 11: 231
   Google Scholar
• Jeunemaitre X., Rigat B., Charru A., Houot A. M., Soubrier F., Corvol P. Sib pair linkage analysis of renin gene haplotypes in human essential hypertension. Hum. Genet. 1992; 88: 301
   PubMed Web of Science ®Google Scholar
• Jeunemaitre X., Soubrier F., Kotelevtsev Y. V., Lifton R. P., Williams C. S., Charru A., Hunt S. C., Hopkins P. N., Williams R. R., Lalouel J. M. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992; 71: 169
   PubMed Web of Science ®Google Scholar
• Pritchard L. E., Kawaguchi Y., Reed P. W., Copeman J. B., Davies J. L., Barnett A. H., Bain S. C., Todd J. A. Analysis of the CD3 gene region and type 1 diabetes: application of fluorescence-based technology to linkage disequilibrium mapping. Hum. Mol. Genet. 1995; 4: 197
   PubMed Web of Science ®Google Scholar
• Davies J. L., Kawaguchi Y., Bennett S. T., Copeman J. B., Cordell H. J., Pritchard L. E., Reed P. W., Gough S. C., Jenkins S. C., Palmer S. M. A genome-wide search for human type 1 diabetes susceptibility genes. Nature, (London) 1994; 371: 130
   PubMed Web of Science ®Google Scholar
• Reed P. W., Davies J. L., Copeman J. B., Bennett S. T., Palmer S. M., Pritchard L. E., Gough S. C., Kawaguchi Y., Cordell H. J., Balfour K. M. Chromosome-specific microsatellite sets for fluorescence-based, semi-automated genome mapping. Nature Genet. 1994; 7: 390
   PubMed Web of Science ®Google Scholar
• Williams R. J. Biochemical Individuality. John Wiley & Sons, New York 1956
   Google Scholar
• Nelson D. B., Nerbert D. W., et al. Pharmacogenetics 1996; 6: 1
   PubMedGoogle Scholar
• Micka, et al. Pharmacogenetics, in press
   Google Scholar
• Daly A. K., et al. Pharmacogenetics 1996; 6: 193
   PubMedGoogle Scholar
• Meyer U. A., personal communication
   Google Scholar
• Shertzer H. G., Nerbert D. W., unpublished data
   Google Scholar